Free Trial
NASDAQ:OTLK

Outlook Therapeutics Q2 2023 Earnings Report

Outlook Therapeutics logo
$1.54 -0.01 (-0.32%)
As of 03:23 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Outlook Therapeutics EPS Results

Actual EPS
-$0.60
Consensus EPS
-$1.20
Beat/Miss
Beat by +$0.60
One Year Ago EPS
N/A

Outlook Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Outlook Therapeutics Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Monday, May 15, 2023
Conference Call Time
4:00PM ET

Upcoming Earnings

Outlook Therapeutics' Q2 2025 earnings is scheduled for Wednesday, May 21, 2025, with a conference call scheduled on Thursday, May 15, 2025 at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Outlook Therapeutics Earnings Headlines

Elon Reveals Why There Soon Won’t Be Any Money For Social Security
Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a terrifying supercar crash with billionaire Peter Thiel, then from a deadly strain of malaria—Elon Musk emerged with a stark warning for Americans about looming financial dangers. Discover the little-known Trump IRS loophole that thousands are now using to safeguard their retirement from inflation and market turmoil—before it's too late.
Outlook Therapeutics management to meet virtually with BTIG
Outlook Therapeutics expands share authorization
See More Outlook Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Outlook Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Outlook Therapeutics and other key companies, straight to your email.

About Outlook Therapeutics

Outlook Therapeutics (NASDAQ:OTLK), operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

View Outlook Therapeutics Profile

More Earnings Resources from MarketBeat